Weiyun Z Ai, MD
Medical Oncology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 4
- Since medical school
- 26 years
- Stanford University School of Medicine, 2000
Offices
4 locations · Regents of the University of California · University of California San Francisco
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ai’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A78202 · Current
Licensed to practise in California · since 2002 · expires 2028-03-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Medical Oncology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$66,609
Medicare paid this office $66,609 for 222 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 87 | $34,293 | $121 |
| Return visit (30+ min) | 112 | $13,188 | $77 |
| New patient visit (60+ min) | 36 | $4,854 | $135 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 124 | $3,421 | $15 |
| Short return visit (20+ min) | 29 | $2,292 | $52 |
See all 6 services
| Long return visit (40+ min) | 87 | $34,293 | $121 |
| Return visit (30+ min) | 112 | $13,188 | $77 |
| New patient visit (60+ min) | 36 | $4,854 | $135 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 124 | $3,421 | $15 |
| Short return visit (20+ min) | 29 | $2,292 | $52 |
| Insertion of needle into vein for collection of blood sample | 20 | $260 | $9 |
Procedures Medicare counted
| Skin biopsy | 1-10 | None |
Who their Medicare patients are
222 Original Medicare patients in 2024. Average age 74 · Under 65 7% · 85 and older 8% · Women 40% · Also on Medicaid 23% · Health risk score 1.99. At or below the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 64% · Diabetes 27% · Chronic kidney disease 27% · Coronary heart disease 25% · Cancer 21% · Atrial fibrillation 20% · Depression 18% · Heart failure 14% · COPD 11% · Stroke 8% · Dementia 5%.
The office billed $541,898, Medicare allowed $89,803 and paid $66,609; for 1,285 services of 43 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 222 | 1,285 | 74 | 1.99 | $541,898 | $66,609 |
| 2023 | 210 | 1,163 | 74 | 2.19 | $467,415 | $64,277 |
| 2022 | 216 | 630 | 72 | 2.29 | $577,950 | $62,990 |
| 2021 | 181 | 585 | 73 | 2.38 | $439,066 | $60,688 |
| 2020 | 173 | 604 | 73 | 2.38 | $500,890 | $52,081 |
| 2019 | 189 | 570 | 73 | 2.59 | $509,380 | $50,287 |
| 2018 | 211 | 658 | 71 | 2.24 | $456,813 | $53,889 |
| 2017 | 187 | 575 | 71 | 2.35 | $446,411 | $43,386 |
| 2016 | 208 | 701 | 69 | 2.42 | $564,081 | $55,891 |
| 2015 | 227 | 805 | 70 | 2.22 | $699,833 | $66,428 |
| 2014 | 195 | 684 | 68 | 2.33 | $655,201 | $54,579 |
| 2013 | 186 | 715 | 69 | 2.22 | $590,966 | $51,618 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Long return visit (40+ min) | 89 | $38,514 | $123 |
| Return visit (30+ min) | 89 | $10,373 | $77 |
| New patient visit (60+ min) | 41 | $6,400 | $156 |
| Short return visit (20+ min) | 23 | $1,694 | $55 |
| Insertion of needle into vein for collection of blood sample | 15 | $269 | $8 |
2022: 5 services
| Long return visit (40+ min) | 88 | $32,966 | $123 |
| Return visit (30+ min) | 101 | $13,080 | $76 |
| New patient visit (60+ min) | 37 | $5,697 | $154 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $5,258 | $91 |
| Short return visit (20+ min) | 13 | $732 | $49 |
2021: 6 services
| Long return visit (40+ min) | 72 | $34,081 | $124 |
| Return visit (30+ min) | 90 | $11,486 | $78 |
| New patient visit (60+ min) | 31 | $5,156 | $166 |
| Return visit (30+ min) | 11 | $1,216 | $87 |
| Short return visit (20+ min) | 18 | $1,047 | $52 |
| Short return visit (20+ min) | 12 | $851 | $57 |
2020: 6 services
| Long return visit (40+ min) | 91 | $33,538 | $91 |
| New patient visit (60+ min) | 33 | $5,011 | $152 |
| Return visit (30+ min) | 63 | $4,937 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,794 | $90 |
| Short return visit (20+ min) | 25 | $1,709 | $45 |
| Extended patient service without direct patient contact, first hour | 13 | $1,328 | $102 |
2019: 5 services
| Long return visit (40+ min) | 99 | $34,068 | $93 |
| Return visit (30+ min) | 53 | $4,416 | $64 |
| New patient visit (60+ min) | 29 | $4,305 | $148 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $3,489 | $92 |
| Short return visit (20+ min) | 26 | $1,425 | $42 |
2018: 7 services
| Long return visit (40+ min) | 76 | $19,362 | $96 |
| Return visit (30+ min) | 97 | $11,793 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $10,098 | $93 |
| New patient visit (60+ min) | 34 | $4,855 | $143 |
| Short return visit (20+ min) | 35 | $2,251 | $44 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,980 | $180 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 12 | $853 | $71 |
2017: 7 services
| Return visit (30+ min) | 98 | $13,501 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $12,075 | $92 |
| Long return visit (40+ min) | 37 | $7,484 | $95 |
| New patient visit (60+ min) | 22 | $3,047 | $138 |
| Short return visit (20+ min) | 26 | $1,569 | $40 |
| Biopsy of bone marrow | 12 | $828 | $69 |
| Short return visit (20+ min) | 15 | $637 | $42 |
2016: 10 services
| Long return visit (40+ min) | 55 | $15,557 | $93 |
| Return visit (30+ min) | 95 | $14,782 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $12,636 | $92 |
| New patient visit (60+ min) | 18 | $2,714 | $151 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,975 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,668 | $64 |
| Short return visit (20+ min) | 27 | $1,330 | $39 |
| Biopsy of bone marrow | 13 | $970 | $69 |
| Hospital discharge day management, 30 minutes or less | 13 | $845 | $65 |
| Short return visit (20+ min) | 12 | $516 | $40 |
2015: 8 services
| Long return visit (40+ min) | 66 | $24,445 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $13,300 | $94 |
| Return visit (30+ min) | 97 | $13,045 | $65 |
| New patient visit (60+ min) | 23 | $3,473 | $151 |
| Short return visit (20+ min) | 47 | $2,590 | $43 |
| Biopsy of bone marrow | 20 | $1,395 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,369 | $65 |
| Hospital discharge day management, 30 minutes or less | 13 | $871 | $67 |
2014: 7 services
| Return visit (30+ min) | 98 | $17,918 | $65 |
| Long return visit (40+ min) | 44 | $14,407 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $10,117 | $93 |
| New patient visit (60+ min) | 16 | $2,388 | $149 |
| Short return visit (20+ min) | 32 | $1,508 | $42 |
| Hospital discharge day management, 30 minutes or less | 12 | $791 | $66 |
| Biopsy of bone marrow | 11 | $765 | $70 |
2013: 6 services
| Return visit (30+ min) | 88 | $22,275 | $64 |
| Long return visit (40+ min) | 34 | $8,790 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $7,422 | $91 |
| New patient visit (60+ min) | 17 | $2,244 | $132 |
| Short return visit (20+ min) | 38 | $2,214 | $41 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,251 | $63 |
Medicaid work
$22,424 in 2024
Medicaid paid $22,424 for 133 billed services this clinician did in 2024, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 133 | $22,424 |
| 2024 | 133 | 1 | 19 | $22,424 |
| 2023 | 35 | 1 | 13 | $6,683 |
| 2021 | 148 | 2 | 16 | $10,726 |
| 2020 | 221 | 2 | 25 | $17,995 |
| 2019 | 338 | 5 | 31 | $19,189 |
| 2018 | 249 | 5 | 19 | $8,172 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 35 | $6,683 |
2021
| Long return visit (40+ min) | 122 | $10,527 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 26 | $200 |
2020
| Long return visit (40+ min) | 200 | $17,402 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 21 | $593 |
2019
| Long return visit (40+ min) | 181 | $14,954 |
| COMPREHENSIVE METABOLIC PANEL | 73 | $2,744 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 54 | $1,009 |
| Lactate dehydrogenase (LD), (LDH) | 15 | $371 |
| Hospital outpatient clinic visit for assessment and management of a patient | 15 | $110 |
2018
| Long return visit (40+ min) | 73 | $5,113 |
| Return visit (30+ min) | 24 | $1,451 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 89 | $985 |
| COMPREHENSIVE METABOLIC PANEL | 49 | $623 |
| Hospital outpatient clinic visit for assessment and management of a patient | 14 | $0 |
Drugs they prescribed that Part D paid
$1,768,035
Pharmacies billed $1,768,035 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (12 of 673) in 2024. At or below the middle of the specialty; the typical medical oncology clinician is at 6%.
545 generic and fewer than 11 brand-name prescriptions · $1,768,035 in drug cost · 35 antibiotic prescriptions to 18 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Brukinsa | 36 | $492,169 | $13,671 |
| Venclexta | 33 | $450,666 | $13,657 |
| Calquence | 16 | $236,062 | $14,754 |
| Bexarotene | 14 | $61,344 | $4,382 |
| Entecavir | 22 | $2,521 | $115 |
See all 18 drugs
| Brukinsa | 36 | $492,169 | $13,671 |
| Venclexta | 33 | $450,666 | $13,657 |
| Calquence | 16 | $236,062 | $14,754 |
| Bexarotene | 14 | $61,344 | $4,382 |
| Entecavir | 22 | $2,521 | $115 |
| Acyclovir | 85 | $1,426 | $17 |
| Valacyclovir | 38 | $1,260 | $33 |
| Clobetasol Propionate | 24 | $1,004 | $42 |
| Ondansetron | 34 | $675 | $20 |
| Triamcinolone Acetonide | 28 | $550 | $20 |
| Gabapentin | 29 | $279 | $10 |
| Levothyroxine | 17 | $218 | $13 |
| Sulfamethoxazole-Trimethoprim | 29 | $124 | $4 |
| Methotrexate | 12 | $116 | $10 |
| Allopurinol | 15 | $107 | $7 |
| Prednisone | 37 | $103 | $3 |
| Oxycodone | 11 | $100 | $9 |
| Atorvastatin | 17 | $78 | $5 |
Year by year
| 2024 | 673 | 104 | 2% (12) | None | $1,768,035 |
| 2023 | 696 | 109 | 2% (11) | None | $1,648,499 |
| 2022 | 703 | 111 | 3% (23) | None | $1,711,774 |
| 2021 | 826 | 95 | 3% (23) | 16% | $1,191,818 |
| 2020 | 618 | 69 | 4% (22) | 14% | $998,725 |
| 2019 | 589 | 70 | None | 16% | $1,005,229 |
| 2018 | 692 | 94 | 4% (28) | None | $649,140 |
| 2017 | 467 | 78 | 3% (12) | 25% | $226,042 |
| 2016 | 525 | 82 | 3% (13) | 14% | $443,958 |
| 2015 | 718 | 89 | 2% (17) | 18% | $398,111 |
| 2014 | 725 | 74 | 3% (23) | None | $327,746 |
| 2013 | 715 | 71 | 5% (33) | None | $298,361 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Brukinsa | 49 | $669,415 | $13,662 |
| Imbruvica | 12 | $304,091 | $25,341 |
| Venclexta | 14 | $211,009 | $15,072 |
| Pegasys | 14 | $60,053 | $4,289 |
| Entecavir | 33 | $15,024 | $455 |
| Acyclovir | 96 | $2,164 | $23 |
| Valacyclovir | 41 | $2,064 | $50 |
| Ondansetron | 40 | $434 | $11 |
| Triamcinolone Acetonide | 17 | $378 | $22 |
| Pregabalin | 11 | $335 | $30 |
| Atorvastatin | 20 | $329 | $16 |
| Gabapentin | 19 | $320 | $17 |
| Levothyroxine | 16 | $215 | $13 |
| Sulfamethoxazole-Trimethoprim | 28 | $117 | $4 |
| Prednisone | 29 | $116 | $4 |
| Pantoprazole | 17 | $107 | $6 |
| Lorazepam | 19 | $70 | $4 |
| Allopurinol | 13 | $65 | $5 |
2022: 15 drugs
| Brukinsa | 36 | $496,378 | $13,788 |
| Revlimid | 17 | $319,231 | $18,778 |
| Imbruvica | 21 | $317,089 | $15,099 |
| Venclexta | 17 | $210,726 | $12,396 |
| Entecavir | 28 | $10,635 | $380 |
| Eliquis | 16 | $8,482 | $530 |
| Valacyclovir | 61 | $4,048 | $66 |
| Acyclovir | 73 | $1,077 | $15 |
| Ondansetron | 28 | $654 | $23 |
| Gabapentin | 39 | $534 | $14 |
| Triamcinolone Acetonide | 21 | $324 | $15 |
| Sulfamethoxazole-Trimethoprim | 39 | $213 | $5 |
| Oxycodone | 11 | $145 | $13 |
| Prednisone | 33 | $137 | $4 |
| Atorvastatin | 17 | $72 | $4 |
2021: 20 drugs
| Imbruvica | 24 | $337,960 | $14,082 |
| Brukinsa | 20 | $271,102 | $13,555 |
| Revlimid | 14 | $240,118 | $17,151 |
| Venclexta | 11 | $116,120 | $10,556 |
| Matulane | 20 | $29,334 | $1,467 |
| Entecavir | 34 | $19,110 | $562 |
| Atovaquone | 16 | $13,115 | $820 |
| Valacyclovir | 102 | $5,003 | $49 |
| Clobetasol Propionate | 35 | $2,490 | $71 |
| Acyclovir | 83 | $1,574 | $19 |
| Ondansetron | 32 | $691 | $22 |
| Prednisone | 63 | $357 | $6 |
| Atorvastatin | 20 | $269 | $13 |
| Gabapentin | 17 | $203 | $12 |
| Oxycodone-Acetaminophen | 14 | $144 | $10 |
| Triamcinolone Acetonide | 13 | $141 | $11 |
| Mupirocin | 12 | $85 | $7 |
| Allopurinol | 11 | $67 | $6 |
| Sulfamethoxazole-Trimethoprim | 12 | $65 | $5 |
| Lorazepam | 12 | $55 | $5 |
2020: 15 drugs
| Imbruvica | 38 | $508,091 | $13,371 |
| Calquence | 17 | $253,393 | $14,905 |
| Entecavir | 40 | $13,441 | $336 |
| Valacyclovir | 85 | $3,849 | $45 |
| Clobetasol Propionate | 23 | $3,027 | $132 |
| Acyclovir | 40 | $964 | $24 |
| Fenofibrate | 20 | $562 | $28 |
| Atorvastatin | 25 | $431 | $17 |
| Ondansetron | 22 | $369 | $17 |
| Gabapentin | 19 | $327 | $17 |
| Oxycodone-Acetaminophen | 14 | $251 | $18 |
| Potassium Chloride | 11 | $155 | $14 |
| Triamcinolone Acetonide | 13 | $134 | $10 |
| Prednisone | 20 | $97 | $5 |
| Lorazepam | 13 | $68 | $5 |
2019: 14 drugs
| Imbruvica | 47 | $580,312 | $12,347 |
| Revlimid | 12 | $187,053 | $15,588 |
| Entecavir | 42 | $20,429 | $486 |
| Clobetasol Propionate | 24 | $4,041 | $168 |
| Valacyclovir | 77 | $2,700 | $35 |
| Acyclovir | 68 | $1,428 | $21 |
| Dapsone | 16 | $1,362 | $85 |
| Gabapentin | 31 | $716 | $23 |
| Triamcinolone Acetonide | 15 | $301 | $20 |
| Atorvastatin | 21 | $275 | $13 |
| Sulfamethoxazole-Trimethoprim | 21 | $244 | $12 |
| Levofloxacin | 12 | $189 | $16 |
| Ondansetron | 12 | $154 | $13 |
| Prednisone | 14 | $103 | $7 |
2018: 15 drugs
| Imbruvica | 18 | $298,018 | $16,557 |
| Entecavir | 42 | $35,455 | $844 |
| Intron A | 20 | $21,608 | $1,080 |
| Clobetasol Propionate | 32 | $10,294 | $322 |
| Valacyclovir | 38 | $1,380 | $36 |
| Dapsone | 28 | $1,159 | $41 |
| Gabapentin | 73 | $1,159 | $16 |
| Triamcinolone Acetonide | 39 | $783 | $20 |
| Acyclovir | 51 | $744 | $15 |
| Atorvastatin | 13 | $309 | $24 |
| Ondansetron | 24 | $246 | $10 |
| Prednisone | 38 | $246 | $6 |
| Sulfamethoxazole-Trimethoprim | 15 | $151 | $10 |
| Lorazepam | 14 | $81 | $6 |
| Hydrocortisone | 11 | $59 | $5 |
2017: 13 drugs
| Clobetasol Propionate | 19 | $4,922 | $259 |
| Valacyclovir | 47 | $1,918 | $41 |
| Sodium Chloride | 41 | $1,385 | $34 |
| Fluocinonide | 11 | $705 | $64 |
| Gabapentin | 24 | $393 | $16 |
| Acyclovir | 24 | $271 | $11 |
| Levofloxacin | 11 | $256 | $23 |
| Tamsulosin | 17 | $229 | $13 |
| Fluconazole | 11 | $159 | $14 |
| Atorvastatin | 12 | $127 | $11 |
| Prednisone | 15 | $110 | $7 |
| Ondansetron | 14 | $100 | $7 |
| Sulfamethoxazole-Trimethoprim | 12 | $43 | $4 |
2016: 15 drugs
| Imbruvica | 21 | $249,819 | $11,896 |
| Entecavir | 14 | $11,189 | $799 |
| Clobetasol Propionate | 15 | $3,894 | $260 |
| Valacyclovir | 78 | $2,061 | $26 |
| Granisetron | 13 | $525 | $40 |
| Gabapentin | 29 | $431 | $15 |
| Ondansetron | 17 | $318 | $19 |
| Tamsulosin | 23 | $233 | $10 |
| Levothyroxine | 17 | $185 | $11 |
| Acyclovir | 12 | $147 | $12 |
| Escitalopram | 11 | $136 | $12 |
| Triamcinolone Acetonide | 15 | $125 | $8 |
| Prednisone | 13 | $119 | $9 |
| Zolpidem | 14 | $73 | $5 |
| Amlodipine Besylate | 21 | $64 | $3 |
2015: 20 drugs
| Revlimid | 14 | $141,056 | $10,075 |
| Enoxaparin | 11 | $8,267 | $752 |
| Clobetasol Propionate | 14 | $6,179 | $441 |
| Valacyclovir | 79 | $2,557 | $32 |
| Granisetron | 32 | $2,401 | $75 |
| Methotrexate | 19 | $1,185 | $62 |
| Fenofibrate | 13 | $738 | $57 |
| Gabapentin | 32 | $607 | $19 |
| Levothyroxine | 35 | $450 | $13 |
| Acyclovir | 29 | $432 | $15 |
| Zolpidem | 19 | $337 | $18 |
| Tamsulosin | 20 | $314 | $16 |
| Triamcinolone Acetonide | 18 | $303 | $17 |
| Pantoprazole | 23 | $283 | $12 |
| Amlodipine Besylate | 50 | $200 | $4 |
| Prednisone | 16 | $140 | $9 |
| Omeprazole | 14 | $124 | $9 |
| Atorvastatin | 13 | $85 | $7 |
| Lorazepam | 14 | $80 | $6 |
| Escitalopram | 11 | $69 | $6 |
2014: 19 drugs
| Targretin | 11 | $176,529 | $16,048 |
| Clobetasol Propionate | 23 | $3,205 | $139 |
| Fenofibrate | 24 | $2,251 | $94 |
| Valacyclovir | 56 | $1,863 | $33 |
| Methotrexate | 24 | $1,606 | $67 |
| Ondansetron | 17 | $463 | $27 |
| Acyclovir | 32 | $435 | $14 |
| Gabapentin | 28 | $423 | $15 |
| Levothyroxine | 35 | $404 | $12 |
| Atorvastatin | 28 | $397 | $14 |
| Zolpidem | 41 | $345 | $8 |
| Pantoprazole | 25 | $330 | $13 |
| Triamcinolone Acetonide | 11 | $256 | $23 |
| Hydrocodone-Acetaminophen | 11 | $192 | $17 |
| Tamsulosin | 13 | $159 | $12 |
| Amlodipine Besylate | 37 | $156 | $4 |
| Omeprazole | 12 | $124 | $10 |
| Sulfamethoxazole-Trimethoprim | 19 | $98 | $5 |
| Lisinopril | 14 | $74 | $5 |
2013: 17 drugs
| Revlimid | 15 | $176,905 | $11,794 |
| Epivir Hbv | 12 | $4,898 | $408 |
| Valacyclovir | 59 | $3,575 | $61 |
| Acyclovir | 57 | $1,042 | $18 |
| Clobetasol Propionate | 20 | $777 | $39 |
| Lansoprazole | 13 | $541 | $42 |
| Potassium Chloride | 12 | $433 | $36 |
| Atorvastatin | 13 | $288 | $22 |
| Hydrocodone-Acetaminophen | 18 | $262 | $15 |
| Sulfamethoxazole-Trimethoprim | 41 | $258 | $6 |
| Gabapentin | 16 | $257 | $16 |
| Zolpidem | 32 | $217 | $7 |
| Amlodipine Besylate | 40 | $198 | $5 |
| Omeprazole | 12 | $170 | $14 |
| Diphenoxylate-Atropine | 12 | $138 | $12 |
| Lorazepam | 22 | $114 | $5 |
| Lisinopril | 13 | $65 | $5 |
Money from drug and device companies
$5,038 in 2025
| 2025 | 4 | 9 | $4,569 | $5,038 |
| 2024 | 4 | 10 | $6,148 | $7,858 |
| 2023 | 6 | 8 | None | $690 |
| 2022 | 3 | 5 | $4,120 | $4,294 |
| 2021 | 3 | 4 | $1,280 | $1,333 |
| 2020 | 2 | 5 | $3,600 | $3,615 |
| 2019 | 3 | 18 | $12,300 | $13,821 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Epkinly | $3,727 | 6 payments
|
| Acrotech Biopharma | Beleodaq | $1,125 | 1 payment
|
| Adc Therapeutics America | None | $104 | 1 payment
|
| Pfizer | Adcetris | $82 | 1 payment
|
See all 9 published payments
| Abbvie | Consulting · 2025-12-15 | None | $3,444 |
| Pfizer | Meals · 2025-12-05 | Adcetris | $82 |
| Abbvie | Meals · 2025-10-25 | Epkinly | $60 |
| Abbvie | Meals · 2025-10-25 | Epkinly | $25 |
| Abbvie | Meals · 2025-10-25 | Epkinly | $70 |
| Abbvie | Meals · 2025-08-27 | Epkinly | $108 |
| Adc Therapeutics America | Meals · 2025-06-17 | None | $104 |
| Abbvie | Meals · 2025-01-30 | Imbruvica | $21 |
| Acrotech Biopharma | Consulting · 2025-01-08 | Beleodaq | $1,125 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $7,858
| Acrotech Biopharma | Beleodaq | $4,654 | 6 payments
|
| Gilead Sciences | None | $3,050 | 1 payment
|
| ADC Therapeutics America | None | $109 | 1 payment
|
| Abbvie | Imbruvica | $45 | 2 payments
|
2023: $690
| AstraZeneca Pharmaceuticals LP | Calquence | $387 | 3 payments
|
| Kyowa Kirin | Poteligeo | $142 | 1 payment
|
| AbbVie | Venclexta | $78 | 1 payment
|
| EMD Serono | Mavenclad | $41 | 1 payment
|
| Genmab U.S. | Epkinly | $25 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $17 | 1 payment
|
2022: $4,294
| Kyowa Kirin | Poteligeo | $2,721 | 3 payments
|
| Secura Bio | Copiktra | $1,500 | 1 payment
|
| Seagen | None | $73 | 1 payment
|
2021: $1,333
| Kite Pharma | Yescarta | $1,280 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $27 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $26 | 2 payments
|
2020: $3,615
| BeiGene USA | Brukinsa | $1,950 | 1 payment
|
| Aurobindo Pharma USA | Beleodaq | $1,665 | 4 payments
|
2019: $13,821
| Kyowa Kirin | Poteligeo | $10,988 | 13 payments
|
| Seattle Genetics | Adcetris | $2,813 | 4 payments
|
| Kite Pharma | Yescarta | $20 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Daiichi Sankyo Inc. · Ds3201-A-U202 · 2022 | Their institution | $195,804 |
| Daiichi Sankyo Inc. · Ds3201-A-U202 · 2024 | Their institution | $152,093 |
| Seagen Inc. · Investigation of Mrd in Untreated T Cell Lymphoma Patients Receiving A Brentuximab-Containing Regimen As the First-Line Therapy · 2023 | Their institution | $67,866 |
| Eli Lilly and Company · A Phase 1/2 Study of Oral Loxo-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll) Or Non-Hodgkin Lymphoma (Nhl) · 2023 | Their institution | $56,148 |
| PFIZER INC. · Investigation of Mrd in Untreated T Cell Lymphoma Patients Receiving A Brentuximabcontaining Regimen As the Firstline Therapy A Pilot Study · 2025 | Their institution | $49,188 |
| Celgene Corporation · Study Evaluating the Safety and Pharmacokinetics of Jcar017 in B-Cell Non-Hodgkin Lymphoma (Transcend-Nhl-001) · 2022 | Their institution | $48,666 |
| PFIZER INC. · Adcetris · 2024 | Their institution | $41,580 |
| Daiichi Sankyo Inc. · Ds3201-A-U202 · 2025 | Their institution | $33,756 |
| Daiichi Sankyo Inc. · Ds3201-A-U202 · 2023 | Their institution | $32,550 |
| Eli Lilly and Company · A Phase 1/2 Study of Oral Loxo-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll) Or Non-Hodgkin Lymphoma (Nhl) · 2025 | Their institution | $29,216 |
| Merck Sharp & Dohme Corporation · Phase 1,2 Study of Intratumoral G100 With Or Without Anti-Pd-1 Antibody Therapy in Patients With Follicular Non-Hodgkin S Lymphoma · 2019 | Their institution | $26,224 |
| Eli Lilly and Company · A Phase 1/2 Study of Oral Loxo-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll) Or Non-Hodgkin Lymphoma (Nhl) · 2024 | Their institution | $26,043 |
| ADC Therapeutics America, Inc. · A Phase 2 Open-Label Single-Arm Study To Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Lotis-2) · 2022 | Their institution | $23,113 |
| ADC Therapeutics America, Inc. · A Phase 2, Open-Label, Single-Arm Study To Evaluate the Efficacy and Safety of Camidanlumab Tesirine (Adct-301) in Patients With Relapsed Or Refractory Hodgkin Lymphoma · 2022 | Their institution | $18,183 |
| Eli Lilly and Company · A Phase 1/2 Study of Oral Loxo-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Cll/Sll) Or Non-Hodgkin Lymphoma (Nhl) · 2022 | Their institution | $15,280 |
| Adaptive Biotechnologies Corporation · Immunoseq · 2025 | Their institution | $12,150 |
| Merck Sharp & Dohme Corporation · Phase 1,2 Study of Intratumoral G100 With Or Without Anti-Pd-1 Antibody Therapy in Patients With Follicular Non-Hodgkin S Lymphoma · 2020 | Their institution | $11,704 |
| Seagen Inc. · Investigation of Mrd in Untreated T Cell Lymphoma Patients Receiving A Brentuximab-Containing Regimen As the First-Line Therapy · 2022 | Their institution | $8,083 |
| Seagen Inc. · A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Sgn-35 and Best Supportive Care (Bsc) Versus Placebo and Bsc in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant · 2020 | Their institution | $4,694 |
| Daiichi Sankyo Inc. · Ds3201-A-U202 · 2021 | Their institution | $1,193 |
| Seattle Genetics, Inc. · A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Sgn-35 and Best Supportive Care Bsc Versus Placebo and Bsc in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant · 2019 | Their institution | $205 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1649346842
- Licence
- CA A78202California A78202: Current · expires 2028-03-31
- Trained
- Stanford University School of Medicine, 2000 · 26 years ago
- Group
- Regents of the University of California · University of California San Francisco
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X)
- Mailing address
- 1635 Divisasdero St, Suite 625, Box 1821, San Francisco, CA, 94143
- NPI first listed
- 2006-11-28
- NPI last updated
- 2008-06-06
This is when the NPI record was last certified, not a medical board exam.